Skip to main content

Table 1 Patients baseline characteristics

From: The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment

Parameters ARMS    
  Control (n=75) Nevirapine (n=128) Efavirenz (n=66) P value
Sex (female) % 65 79.5 52.3  
Median age in years 38 (19–64) 42 (21–67) 43 (39–66) 0.015
Temperature mean, SD ± OC 38.1 ± 0.8 37.8 ± 1.3 38.3± 0.9 0.485
Median weight (IQR) 56 (41–92) 55 (41–78) 58 (36–84) 0.953
Median (range) parasite density/μL 1280 (560–4040) 4040 (600–261520) 3440 (480–126960) 0.564
Haemaglobin (g/dL) median (IQR) 13.9 (12.2-15.2) 12.1 (11.2-13.5) 12.3 (10.2-13.6) 0.036
CD4+ count (x106/L) median (IQR) 402 (66–964) 354 (19–1781) 298 (9–694) 0.002